This MedLibrary.org supplementary page on Epoprostenol is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Epoprostenol
|
|
| Systematic (IUPAC) name | |
| (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4- [(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a- hexahydrocyclopentadfuran-2-ylidene]pentanoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | B01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H32O5 |
| Mol. mass | 352.465 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | Not applicable (IV only) |
| Metabolism | To 6-keto-PGF1α and 6,15-diketo-13,14-dihydro-PGF1α |
| Half life | 6 minutes (in vitro) |
| Excretion | Renal |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
B(US) |
| Legal status |
℞ Prescription only |
| Routes | Intravenous |
Epoprostenol is a synthetic form of prostacyclin, and is used to treat pulmonary hypertension. It is sold under the trade name Flolan.
Contents |
Clinical pharmacology
As an analogue of prostacyclin PGI2, epoprostenol effects vasodilation, which in turn lowers the blood pressure. Epoprotstenol also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.
Administration
Epoprostenol is given via continuous infusion that requires a semi-permanent central venous catheter. This means that the patient must be attached to an infusion pump at all times. This delivery system can cause sepsis and thrombosis. Because epoprostenol is unstable, it must be kept cold, even during administration. Since it has a half-life of 3 to 5 minutes, the infusion has to be continuous (24/7), and an interruption can lead to a potentially fatal rebound of symptoms.
History
Epoprostenol was developed by GlaxoSmithKline and approved in the USA as a medicine in 1995.
Marketing
It was licensed to Myogen, which was subsequently acquired by Gilead Sciences. Flolan is marketed in the United States by Gilead Sciences and elsewhere by GlaxoSmithKline.
|
||||||||||||||
|
||||||||
Wikipedia content modification information:
- This page was last modified on 15 November 2007, at 21:19.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Epoprostenol".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.